Research programme: kinase inhibitors - Hanmi PharmaceuticalAlternative Names: HM 571B; HM 60781
Latest Information Update: 09 Aug 2010
At a glance
- Originator Hanmi Pharmaceutical
- Mechanism of Action Epidermal growth factor receptor antagonists; Protein tyrosine kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 26 Feb 2007 Preclinical trials in Cancer in South Korea (unspecified route)